• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 3. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 4. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 5. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Halopyridines Polyhalopyridines

Research Brief on 3-Pyridineacetonitrile, 5,6-dichloro- (CAS: 54226-45-8) in Chemical Biology and Pharmaceutical Applications

3-Pyridineacetonitrile, 5,6-dichloro- (CAS: 54226-45-8) is a chlorinated pyridine derivative that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound, characterized by its nitrile and dichloro-substituted pyridine ring, serves as a key intermediate in the synthesis of bioactive molecules, including kinase inhibitors and antiviral agents. Recent studies have highlighted its potential in drug discovery, particularly in targeting protein-protein interactions and modulating enzymatic activity.

A 2023 study published in the Journal of Medicinal Chemistry explored the use of 3-Pyridineacetonitrile, 5,6-dichloro- as a scaffold for developing selective kinase inhibitors. The research team employed structure-activity relationship (SAR) analysis to optimize the compound's binding affinity for specific kinase targets, demonstrating its efficacy in inhibiting aberrant signaling pathways associated with cancer. The study reported a 40% improvement in inhibitory potency compared to earlier analogs, underscoring the compound's potential in oncology therapeutics.

In addition to its role in kinase inhibition, recent investigations have revealed the compound's utility in antiviral drug development. A 2024 preprint in BioRxiv detailed its incorporation into nucleoside analogs, where it exhibited promising activity against RNA viruses, including SARS-CoV-2 variants. The dichloro-substitution was found to enhance metabolic stability, addressing a common limitation in antiviral prodrug design. These findings position 3-Pyridineacetonitrile, 5,6-dichloro- as a valuable building block for next-generation antiviral agents.

From a synthetic chemistry perspective, advancements in the scalable production of 3-Pyridineacetonitrile, 5,6-dichloro- have been reported in Organic Process Research & Development (2023). Researchers developed a novel catalytic system using palladium nanoparticles, achieving an 85% yield with reduced environmental impact compared to traditional methods. This breakthrough addresses supply chain challenges for pharmaceutical manufacturers relying on this intermediate.

Ongoing clinical trials (Phase I/II) are evaluating derivatives of 3-Pyridineacetonitrile, 5,6-dichloro- as potential treatments for neurodegenerative diseases. Preliminary data presented at the 2024 American Chemical Society meeting suggests these compounds can cross the blood-brain barrier and exhibit neuroprotective effects in animal models of Parkinson's disease. The mechanism appears to involve modulation of mitochondrial function and reduction of oxidative stress.

Future research directions for 3-Pyridineacetonitrile, 5,6-dichloro- include exploration of its chiral derivatives for asymmetric synthesis applications and investigation of its photophysical properties for biosensing applications. The compound's unique electronic configuration, resulting from the electron-withdrawing chloro and nitrile groups, makes it particularly interesting for materials science applications in organic electronics.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)